Cinven eyes US medtech firms looking to Europe

Cinven currently has just two healthcare investments: Labco, and US pharma contract research group Medpace, which it acquired for $915 million in 2014.

Cinven’s healthcare team partner Alex Leslie believes that despite a recent tough patch for the pharmaceutical sector, optimism remains intact among many of the companies he spoke to at the JPM Global Healthcare conference.

Comments from Democratic presidential frontrunner Hillary Clinton on targeting a reduction in drug prices sparked a near 20 percent drop in the US listed pharmaceutical sector last October and it has struggled to regain much of that ground since.

Leslie told Private Healthcare Investor: “The more established pharma market has had a rocky couple of months driven largely about reforms on US drug pricing, but when you talk to companies, they are very clear on what they are doing and particularly around what will create value in the future.”

“[At the conference] there is a lot of talk around genetics and the way sequencing is progressing, which is relevant to our diagnostics investments.” 

Cinven is currently focusing on US medtech firms that are considering Europe as a market their products for the first time.

Read more by visiting